Beam Therapeutics BEAM 深 滬
交易中 09-24 12:06:42 美东时间
24.01
-0.360
-1.48%
華盛通- 最 高24.365
- 今 開23.82
- 成交量 112.49万股
- 最 低 23.16
- 昨 收 24.37
- 總市值 24.80亿
- 52周最高 38.26
- 市盈率 靜 --
- 換手率 1.09%
- 52周最低 20.23
- 委 比 -90.95%
- 總股本 1.03亿
- 歷史最高 138.522
- 量 比 1.51
- 振 幅 4.94%
- 歷史最低 13.00
- 每 手 1
- 風險率 3.31%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Anthropic IPO前亮科研牌：Claude“自主发现”类CRISPR系统，基因编辑板块遭遇“AI替代焦虑”
周三，美股基因编辑公司股价走低。此前，Anthropic宣布，其AI模型Claude“自主发现”了一种类似于基因编辑工具CRISPR的新型酶系统。 个股方面，...
09-24 07:21
Gene editing stocks fall after Anthropic’s CRISPR-like discovery
Gene editing companies traded lower on Wednesday after Anthropic (ANTHRO) said that its AI model Claude has “autonomously discovered” a new enzyme system similar to the gene-editing tool CRISPR. Notab...
09-24 02:33
Muse一夜爆红！“木头姐”大手笔增持Meta，加码医疗与生物科技
当地时间9月22日，“木头姐”Cathie Wood旗下方舟投资（ARK Invest）公布的每日交易纪录显示，持股重心明显偏向大型AI平台与基因精准医疗，同时...
09-23 09:49
Cathie Wood Loads Up On Biotech: 5 ETFs Holding Her Latest Bets
Cathie Wood is doubling down on biotech, but investors looking beyond her ARK Genomic Revolution ETF (BATS:ARKG) have several other ways to gain exposure to the same companies. ARKG bought about $4.5 million of Ionis Pharmaceuticals Inc (NASDAQ:IONS), nearly $3 million of Veracyte Inc (NASDAQ:VCYT),...
09-22 22:40
美股知名投资人最新调仓曝光：“木头姐”大举买入Meta，同时减持CrowdStrike
“木头姐”凯茜·伍德旗下ARK Invest公布9月21日交易记录，当天最受关注的操作是大举买入Meta，同时减持CrowdStrike，并继续调整医疗科技...
09-22 14:42
美股大行评级 | 戴尔、Adobe获大行上调目标价；甲骨文绩前目标价遭调低
今日重点评级关注：富国银行：维持Pyxis Oncology"超配"评级，目标价从12美元升至19美元；Oppenheimer：维持Opus Genetics"跑赢大市"评级，目标价从10美元升至20美元
09-10 15:00
Beam Therapeutics Announces Updated Clinical Data From Its Phase 1/2 Trial Evaluating BEAM-302 For Alpha-1 Antitrypsin Deficiency; BEAM-302 Continues To Demonstrate Potential As One-Time Treatment For Both Lung And Liver Manifestations Of AATD
With Up to 18 Months Follow-Up, Data Show Long-Term Durability of In Vivo Correction of Disease-causing Mutation with Single Dose of BEAM-302 Treatment with BEAM-302 Increased Total and Functional AAT and Decreased Neutrophil Elastase Activity in Circulation BEAM-302 Led to Reduction in Circulating ...
09-08 18:05
Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026
BEAM-302, a liver-targeted base editing therapy, shows promise as a one-time treatment for alpha-1 antitrypsin deficiency (AATD), addressing both lung and liver manifestations. Clinical data from a Phase 1/2 trial demonstrate sustained increases in functional AAT levels, reduction in mutant Z-AAT and toxic Z-polymers, and improved AAT function under physiological control. The treatment was generally well-tolerated, with mild-to-moderate infusion-...
09-08 10:00
Most shorted stocks on Wall Street
As September begins, investors are keeping a close eye on heavily shorted stocks that could see heightened volatility. The latest mid- to mega-cap screen shows 44 stocks with short interest above 20% ...
09-02 22:28
Beam Therapeutics Appoints Eric Foster as Chief Commercial Officer
Beam Therapeutics appoints Eric Foster as Chief Commercial Officer to lead its commercial strategy and preparations for the potential 2027 launch of risto-cel. Foster, with over 25 years of experience in biopharmaceuticals, including successful leadership at Horizon Therapeutics and Ardelyx, will help build a strong commercial organization and advance the company's precision genetic medicines pipeline.
09-01 11:00
